Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to “Hold”

Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by analysts at Royal Bank Of Canada from a “moderate buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other equities analysts also recently commented on EYPT. Cantor Fitzgerald downgraded shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday. Guggenheim reissued a “buy” rating and issued a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Stifel Nicolaus began coverage on Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $40.00 target price for the company. HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Finally, Citigroup reduced their price target on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.11.

Eyepoint Pharmaceuticals Stock Up 12.3%

NASDAQ EYPT opened at $5.47 on Monday. The company has a fifty day moving average of $12.97 and a two-hundred day moving average of $13.55. The firm has a market capitalization of $471.57 million, a price-to-earnings ratio of -1.46 and a beta of 1.76. Eyepoint Pharmaceuticals has a 52 week low of $3.95 and a 52 week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The firm had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. Equities research analysts anticipate that Eyepoint Pharmaceuticals will post -3.6 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV bought a new stake in Eyepoint Pharmaceuticals during the 1st quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after acquiring an additional 1,358 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Eyepoint Pharmaceuticals during the third quarter worth approximately $76,000. Tower Research Capital LLC TRC increased its position in shares of Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after acquiring an additional 5,967 shares during the period. Finally, California State Teachers Retirement System raised its stake in shares of Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after acquiring an additional 794 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals News Roundup

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Citigroup maintained a Buy rating while lowering its price target to $17, implying substantial potential upside from current levels. Jefferies also retained a Buy rating, with an $8 target. Benzinga analyst coverage
• Positive Sentiment: Although DURAVYU missed the full-study primary endpoint, EyePoint said the drug was non-inferior to aflibercept in an ad hoc analysis excluding an asymmetric group of patients whose vision loss was unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, durable disease control, supplement-free treatment rates and a favorable redosing safety profile. EyePoint LUGANO trial announcement
• Neutral Sentiment: Unusual options activity was reported, with traders purchasing 3,011 call contracts, about 19% above average call volume. This may reflect speculative expectations for a recovery but does not change the trial outcome.
• Neutral Sentiment: Trading in EYPT was temporarily halted for news before the trial results were released, underscoring the market sensitivity surrounding the announcement.
• Negative Sentiment: The full LUGANO dataset missed the primary endpoint, triggering a roughly two-thirds collapse in the stock and raising questions about DURAVYU’s regulatory path and commercial prospects. The result was widely described as a late-stage trial failure. Reuters trial report
• Negative Sentiment: Analyst sentiment became more cautious: Cantor Fitzgerald downgraded EYPT to Neutral, while Chardan, RBC, JPMorgan and HC Wainwright maintained neutral or sector-perform views. Chardan cut its target to $5 from $65, and RBC and Chardan both set $5 targets, indicating limited near-term upside.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.